当前位置: 首页 > 期刊 > 《医药产业资讯》 > 2011年第18期 > 正文
编号:12164243
乳腺癌患者综合治疗的疗效及预后分析(1)
http://www.100md.com 2011年6月25日 沈伟娟 凌立君
第1页

    参见附件(3029KB,3页)。

     [摘要] 目的:探讨可手术的乳腺癌患者综合治疗的疗效、预后及主要影响因素。方法:收集2002年1月~2005年12月236例可手术的乳腺癌患者的临床病理资料,探讨患者的年龄、绝经与否、肿瘤大小、腋窝淋巴结转移数量、TNM分期、激素受体表达情况、化疗、放疗及内分泌治疗的疗效与预后的相关性。结果:236例患者5年生存率为68.6%。肿瘤大小、腋窝淋巴结转移数目及TNM分期与患者生存率呈负相关(P<0.05)。其中三阴性乳腺癌的生存率较非三阴乳腺癌明显降低(P=0.022)。术后进行化疗、放射治疗或内分泌治疗的患者5年生存率均高于未进行综合治疗的患者(P<0.05)。年龄、绝经与否、激素受体表达与5年生存率无明显相关(P>0.05)。结论:肿瘤大小、腋窝淋巴结转移数目、TNM分期、三阴性乳腺癌以及术后是否进行化疗、内分泌治疗、放射治疗均与预后有密切关系。其中肿瘤大小、腋窝淋巴结转移数目和TNM分期为影响乳腺癌患者预后的独立危险因素。

    [关键词] 乳腺癌;综合治疗;预后

    [中图分类号] R737.9 [文献标识码] A [文章编号] 1673-7210(2011)06(c)-069-03

    Clinical analysis of synthetic therapy effect and prognostic factors in breast cancer patients

    SHEN Weijuan1,3, LING Lijun2

    1.Nanjing Medical University, Nanjing 210029, China; 2.Department of Breast Cancer, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China; 3.Department of Breast Cancer, the Affiliated Wujin Hospital of Jiangsu University, Changzhou 213000, China

    [Abstract] Objective: To analyze the synthetic therapy effect and prognostic factors in the patients with breast cancer. Methods: From January 2002 to December 2005, the clinical-pathological materials of 236 breast cancer patients who had received synthetic therapy, including surgery, chemotherapy, endocrine therapy and radiotherapy were analyzed. The corre-lation of age, menopausal status, tumor size, axillary lymphnodal status, TNM stage, hormone receptor status, chemotherapy, endocrine therapy and radiotherapy with prognosis of breast cancer were evaluated. Results: The 5-year survival rates for patients was 68.6%. Analysis revealed that 5-year survival rates of this group were significantly associated with tumor size, axillary lymph nodal status and TNM stage (P<0.05). The 5-year survival rates of the patients with triplenegative breast cancer (TNBC) were lower than the not triplenegative breast cancer (P=0.022). Chemotherapy, endocrine therapy and radiotherapy can improve the 5-year survival rates (P<0.05). Patients'age, menopause status and hormone receptor status had no significant independent prognostic value(P>0 ......

您现在查看是摘要介绍页,详见PDF附件(3029KB,3页)